Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Trading Up 8.4 %

TRVN stock opened at $4.01 on Friday. Trevena has a 12 month low of $3.35 and a 12 month high of $25.75. The company has a 50-day moving average price of $2.86 and a 200 day moving average price of $1.25. The stock has a market cap of $73.55 million, a PE ratio of -1.50 and a beta of 1.03.

Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.36. The firm had revenue of $0.33 million for the quarter.

Institutional Investors Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC acquired a new stake in Trevena, Inc. (NASDAQ:TRVN) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.